{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:14:20Z","timestamp":1791818060677,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.bone.2016.11.024","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T03:20:45Z","timestamp":1479871245000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Sclerostin expression and functions beyond the osteocyte"],"prefix":"10.1016","volume":"96","author":[{"given":"Megan M.","family":"Weivoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merry Jo","family":"Oursler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.bone.2016.11.024_bb0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am. J. Med. Genet."},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0030","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jbmr.307","article-title":"Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones","volume":"26","author":"Ominsky","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.11.024_bb0035","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"23","key":"10.1016\/j.bone.2016.11.024_bb0045","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bone.2016.11.024_bb0050","article-title":"Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis","author":"Guanabens","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jbmr.2690","article-title":"Isolation and functional analysis of an immortalized murine cementocyte cell line, IDG-CM6","volume":"31","author":"Zhao","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019595","article-title":"The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bone.2016.11.024_bb0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.37802","article-title":"Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury","volume":"65","author":"Roudier","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.bone.2016.11.024_bb0070","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","article-title":"Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis","volume":"60","author":"Appel","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/dvdy.21054","article-title":"SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development","volume":"236","author":"van Bezooijen","year":"2007","journal-title":"Dev. Dyn."},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ydbio.2013.08.015","article-title":"Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner","volume":"383","author":"Collette","year":"2013","journal-title":"Dev. Biol."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ydbio.2010.03.021","article-title":"Genetic evidence that SOST inhibits WNT signaling in the limb","volume":"342","author":"Collette","year":"2010","journal-title":"Dev. Biol."},{"issue":"6","key":"10.1016\/j.bone.2016.11.024_bb0090","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.bone.2016.11.024_bb0095","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralized matrices and van Buchem disease","volume":"88","author":"van Bezooijen","year":"2009","journal-title":"J. Dent. Res."},{"issue":"7","key":"10.1016\/j.bone.2016.11.024_bb0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.joca.2011.04.014","article-title":"Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis","volume":"19","author":"Chan","year":"2011","journal-title":"Osteoarthr. Cartil."},{"issue":"4","key":"10.1016\/j.bone.2016.11.024_bb0105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.joca.2009.12.002","article-title":"Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis","volume":"18","author":"Karlsson","year":"2010","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.bone.2016.11.024_bb0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13075-015-0674-6","article-title":"DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter","volume":"17","author":"Papathanasiou","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"330","key":"10.1016\/j.bone.2016.11.024_bb0115","doi-asserted-by":"crossref","first-page":"330ra35","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0120","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s13075-014-0460-x","article-title":"Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis","volume":"16","author":"Brabnikova-Maresova","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.bone.2016.11.024_bb0125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ncprheum0904","article-title":"Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis","volume":"4","author":"Corr","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0130","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/labinvest.2015.142","article-title":"Wnt signaling in cartilage development and diseases: lessons from animal studies","volume":"96","author":"Usami","year":"2016","journal-title":"Lab. Investig."},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00198-009-0931-0","article-title":"Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study","volume":"21","author":"Velasco","year":"2010","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1359\/jbmr.080901","article-title":"Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice","volume":"24","author":"Zhu","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.bone.2016.11.024_bb0150","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/art.39508","article-title":"Endochondral growth defect and deployment of transient chondrocyte behaviors underlie osteoarthritis onset in a natural murine model","volume":"68","author":"Staines","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2016.11.024_bb0155","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2016.11.024_bb0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13075-015-0540-6","article-title":"Loss of sclerostin promotes osteoarthritis in mice via beta-catenin-dependent and -independent Wnt pathways","volume":"17","author":"Bouaziz","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.bone.2016.11.024_bb0165","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/jbmr.70","article-title":"Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture","volume":"25","author":"Power","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"7\u20138","key":"10.1016\/j.bone.2016.11.024_bb0170","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clinbiochem.2014.03.011","article-title":"Plasma and synovial fluid sclerostin are inversely associated with radiographic severity of knee osteoarthritis","volume":"47","author":"Mabey","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bone.2016.11.024_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/8756-3282(93)90350-J","article-title":"Hip fracture and the MEDOS Study Osteoarthritis protects against femoral neck fracture: the MEDOS study experience","volume":"14","author":"Dequeker","year":"1993","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.11.024_bb0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00003086-198612000-00005","article-title":"Role of subchondral bone in the initiation and progression of cartilage damage","volume":"213","author":"Radin","year":"1986","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0185","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/rheumatology\/keu425","article-title":"Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation","volume":"54","author":"Sakellariou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.bone.2016.11.024_bb0190","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/annrheumdis-2013-203630","article-title":"Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis","volume":"73","author":"Tsui","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.bone.2016.11.024_bb0195","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1359\/jbmr.090305","article-title":"Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNF\u03b1 induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts","volume":"24","author":"Vincent","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2016.11.024_bb0200","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/annrheumdis-2013-203345","article-title":"Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis","volume":"72","author":"Chen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0205","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bone.2016.11.024_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/his.12953","article-title":"Sclerostin expression in bone tumours and tumour-like lesions","author":"Inagaki","year":"2016","journal-title":"Histopathology"},{"issue":"14","key":"10.1016\/j.bone.2016.11.024_bb0215","doi-asserted-by":"crossref","first-page":"13849","DOI":"10.1074\/jbc.M306249200","article-title":"Cbfa1\/RUNX2 directs specific expression of the sclerosteosis gene (SOST)","volume":"279","author":"Sevetson","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.11.024_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1; a potential therapeutic strategy for myeloma bone disease","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.bone.2016.11.024_bb0230","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0235","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bone.2016.11.024_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bone.2016.11.024_bb0245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0250","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1186\/bcr3048","article-title":"Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2\/CBFbeta-dependent expression of the Wnt antagonist, sclerostin","volume":"13","author":"Mendoza-Villanueva","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.bone.2016.11.024_bb0255","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/modpathol.2008.94","article-title":"The prognostic significance of BMP-6 signaling in prostate cancer","volume":"21","author":"Yuen","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bone.2016.11.024_bb0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13578-016-0091-9","article-title":"SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation","volume":"6","author":"Liu","year":"2016","journal-title":"Cell Biosci."},{"issue":"11","key":"10.1016\/j.bone.2016.11.024_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142058","article-title":"SOST inhibits prostate cancer invasion","volume":"10","author":"Hudson","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2012.04.016","article-title":"Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover","volume":"51","author":"Yavropoulou","year":"2012","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0275","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-013-2462-y","article-title":"Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids","volume":"25","author":"Garcia-Fontana","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.11.024_bb0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","article-title":"Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study","volume":"14","author":"Brandenburg","year":"2013","journal-title":"BMC Nephrol."},{"issue":"12","key":"10.1016\/j.bone.2016.11.024_bb0285","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1210\/jc.2015-3056","article-title":"Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients","volume":"100","author":"Evenepoel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2016.11.024_bb0290","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1210\/jc.2013-1521","article-title":"Sclerostin: another vascular calcification inhibitor?","volume":"98","author":"Claes","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.11.024_bb0295","article-title":"High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study","author":"Drechsler","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.bone.2016.11.024_bb0300","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/alcalc\/ags136","article-title":"Serum sclerostin in alcoholics: a pilot study","volume":"48","author":"Gonzalez-Reimers","year":"2013","journal-title":"Alcohol Alcohol."},{"issue":"5","key":"10.1016\/j.bone.2016.11.024_bb0305","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00774-013-0524-z","article-title":"Effect of liver dysfunction on circulating sclerostin","volume":"32","author":"Rhee","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2016.11.024_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2013.10.019","article-title":"Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans","volume":"59","author":"Roforth","year":"2014","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0315","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"Modder","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.11.024_bb0320","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"26","key":"10.1016\/j.bone.2016.11.024_bb0325","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M301716200","article-title":"Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity","volume":"278","author":"Kusu","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bone.2016.11.024_bb0330","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/jcb.24537","article-title":"Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization","volume":"114","author":"Ota","year":"2013","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.bone.2016.11.024_bb0335","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0765.2009.01227.x","article-title":"Localization of SOST\/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro","volume":"45","author":"Jager","year":"2010","journal-title":"J. Periodontal Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821630357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821630357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:23:15Z","timestamp":1718896995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821630357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":67,"alternative-id":["S875632821630357X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.11.024","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sclerostin expression and functions beyond the osteocyte","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}